Kaposi’s Sarcoma-Associated Virus Governs Gene Expression Profiles Toward B Cell Transformation

Keiji Ueda1, Emi Ito2, Masato Karayama3, Eriko Ohsaki1, Kazushi Nakano1 and Shinya Watanabe2

1Division of Virology, Department of Microbiology and Immunology Osaka University Graduate School of Medicine
2Department of Clinical Genomics, Translational Research Center Fukushima Medical University
3Department of Infectious Diseases, Hamamatsu University School of Medicine Japan

1. Introduction

Kaposi’s sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8) was found in patients’ specimens as a causative agent of Kaposi’s sarcoma by representational difference analysis (RDA) (Chang et al., 1994). Initially identified fragments by RDA were KS330Bam and KS631Bam, which showed a sequence similarity to a portion of the open reading frame (ORF) 26 open reading frame encoding the capsid protein VP23 of herpesvirus saimiri (HVS) and the amino acid sequence encoded by the corresponding BDLF1 ORF of Epstein-Barr virus (EBV), and to the tegment protein, ORF75 and also the tegment protein of EBV, BNRF1 (p140), respectively. The following full sequence analysis revealed that KSHV was belonging to the \(\gamma\)-herpesvirus subfamily, the genus rhadinovirus rather than lymphocryptic virus and could be a new oncogenic DNA virus (Moore et al., 1996; Russo et al., 1996).

KSHV is supposed to infect various kinds of tissue in vitro at least by using integrin \(\alpha V \beta 3\) as a receptor (Garrigues et al., 2008) and establishes latency in B cells (Chen and Lagunoff, 2005). KSHV has been reported to infect a primary endothelial cell and can transform it into a spindle cell which is a characteristic feature of the oncogenic activity of KSHV in endothelial cells (Lagunoff et al., 2002) However, it has not been revealed effective in vitro infection to primary peripheral blood mononuclear cells (PBMC), which of course include B cell, as EBV can form lymphoblastoid cell lines (LCL). Extensive studies so far have revealed that KSHV should be an etiologic agent for Kaposi’s sarcoma (KS), multicentric Castleman’s disease (MCD), and primary effusion lymphoma (PEL) (Hengge et al., 2002a; Hengge et al., 2002b).

It is quite a big question how oncogenic viruses are involved in their related cancers. Especially limited host ranges of viruses only infecting with humans make this question more unanswerable. One approach to get a hint about this question and solve it is to see gene expression profiles of viruses-associated tumors. Recently, we analyzed three types of typical lymphocyte-originated tumor cell lines-primary effusion lymphoma (PEL) cell lines,
T cell leukemia cell lines (TCL), Burkitt lymphoma (BL) cell lines-and two sets of PBMCs-in order to know how PEL was generated by searching characteristic gene expression profiles. Our approach, however, might be just to show typical gene expression profiles after establishment of PEL cell lines and it may be very difficult to account for viral pathogenesis only by gene expression profiles. Needless to say, we need an experimental model to observe the whole process from virus infection to cancer formation. In this chapter, we discuss about how KSHV is involved in PEL formation and what to do next to solve questions about viral oncogenesis.

2. Characteristic features of KSHV

KSHV is a γ-herpesvirus mentioned above and the genome is double stranded linearized DNA about 170kb long including GC-rich repetitious repeat called terminal sequences (TR), the unit of which is 801bp and repeated 30~50 times at the end of the genome though the sequence and the repeated unit might be different among clones. The unique region of the genome is about 140kb long and encodes more than 80 genes, most of which are lytic genes (Russo et al., 1996). The linearized genome is circularized at the TR after entry into cells and usually stealthies as an episome not going to full lytic replication.

2.1 KSHV life cycles

Like the other herpesviruses, KSHV has two typical life cycles called lytic infection (or reactivation from latency) and latent infection. Lytic infection/reactivation is a virus producing cycle and probably all viral genes are expressed from immediate early (IE), early (E) and late (L) genes in a cascade-like fashion. A key factor for lytic replication is Reactivation Transcription Activator (RTA) (Chen et al., 2001; Lukac et al., 1998; Sun et al., 1998). RTA is a very strong transactivator and trans-activates the other viral E genes such as K-bZIP (K8), orf57, pan including kaposin (k12), a latent gene, not only through specific binding sequences but also through an indirect mechanism (Sakakibara et al., 2001). When L genes are successfully expressed, it leads to explosive daughter virus production, which is a final end of the viral life cycle to disseminate viral infection and survive as its virus itself in nature. On the other hand, latent infection is a viral stealthing state. The viral genome replicates according to the host cell cycle and is partitioned into divided cells at least in KSHV infected PEL cell lines (Ballestas, Chatis, and Kaye, 1999). The viral copy number per cell appears to be maintained at the same (Ueda et al., 2006). In this state, expressing viral genes are extremely limited to a few genes such latency-associated nuclear antigen (lana), viral cyclin (v-cyc), viral flip (v-flip), kaposin (k12) and viral interferon regulatory factor 3 (v-irf-3) (Paulose-Murphy et al., 2001). The former three genes are actually in one unit of gene (Fig. 1). lana and v-cyc-v-flip expression is regulated by alternative splicing. v-cyc-v-flip is in one transcript and v-FLIP is translated through internal ribosome entry site (IRES). Although k12 is an independent gene, these four genes are present in one region and actively expressed. It remains to be solved how latent genes are regulated, since neighbor genes just upstream or downstream are tightly inactivated in a high density of genes in the genome. Epigenetic marking might be important to establish this state but it is unclear how such an effect itself is controlled (Toth et al., 2010). As for a virus, latency is a kind of poised state waiting for lytic replication, because it could be unfavorable for the virus to disseminate and expand its generation.
Kaposi’s Sarcoma-Associated Virus Governs Gene Expression Profiles Toward B Cell Transformation

95

Fig. 1. The active gene locus around lana.

The viral latency might be the places for KSHV-associated malignancies mentioned below, since such malignancies usually show viral latent infection. And therefore, it seems to be quite important to understand what the viral latency is and it will give us hints to investigate functions of the viral latent genes products. Nevertheless, if the viral latent genes products work for cellular immortalization and/or transformation, there may be more patients in KSHV infected people suffering from KSHV-associated malignancies. Thus, it should be kept in our mind to take this idea into consideration when thinking how KSHV is involved in cancer formation.

2.2 Latency-associated nuclear antigen (LANA)
LANA is one of the most actively produced viral factors and controls the viral latency. Though LANA seems to be a multifunctional protein, important functions of LANA in the latency are to support the viral genome replication, to partition the replicated viral genome and to maintain the same genome copy number per cell, and to regulate the viral genes expression (Han et al., 2010).
LANA has two binding sites called LANA binding sequences (LBS) in TR and replication origin of the KSHV genome in latency (ori-P) consists of the LBS and the following 32bp GC-rich segment (32GC) (Garber, Hu, and Renne, 2002; Garber et al., 2001). One of two LBS is required for the viral replication at least but it is not enough, i.e., 32GC is also required (Hu and Renne, 2005). Though it remains to be solved how the viral ori-P is determined among repeated TR sequences and how 32GC is functioning, LANA has been reported to interact with components of cellular replication machinery; origin recognition complex 1 to 6 (ORC1~ORC6) (Verma et al., 2006). Probably LANA binds with LBS and recruits ORCs on the ori-P to start replication. It is, however, very questionable whether LANA binds all ORCs at the same time. LANA also interacts with a histone acetyltransferase binding to ORC1 (HBO1) and epigenetic control around ori-P is may be more important (Stedman et al., 2004).
LANA is supposed to interact with a chromosome component, since the viral genomes are found in the vicinity of chromosomes and actually reported to bind with a histone such as H2B, and with Bub1, CENP-F and so on (Barbera et al., 2006; Xiao et al., 2010). Such interaction might account for the viral genome partition and maintenance, though the detail is unclear.
LANA regulates the viral genes expression and maybe cellular gene expression by interacting with components involved in heterochromatin formation such as heterochromatin protein 1 (HP1) and histone methyl transferase, suv39H1. LANA binds with LBS and recruits such
factors on the viral genome, which forms heterochromatin-like environment of the genome and as a whole inactive gene expression (Sakakibara et al., 2004). Viral genes expressed in the latency might have oncogenic activities because KSHV-associated malignancies are usually in latency setting. Multifunctional LANA interacts with many cellular factors other than those mentioned above. Several mechanisms are thought how LANA works in the viral oncogenesis. LANA interacts with suppressive oncogenes such as p53 (Friborg et al., 1999) as the other oncogenic DNA viral genes products. We have confirmed that LANA interacts with p53 to degrade (Suzuki et al., 2010) but not pRb (our personal observation). It was also reported that LANA interacted with glycogen synthase kinase 3β (GSK3β) and blocked β-catenin degradation pathway that was promoted β-catenin phosphorylation by GSK3β (Liu et al., 2007). On the other hand, stably LANA expressing cells are, however, very difficult to establish, which means that LANA expression might give disadvantage for cell growth rather than cell growth promotion (our personal observation).

2.3 Viral cyclin (v-CYC)
KSHV encodes a cyclin D homologue termed v-cyclin, which is translated from alternatively spliced mRNA covering the lana-v-cyc-v-flip region (Li et al., 1997) (Fig. 1). v-CYC interacts with cyclin dependent kinase 6 (CDK6) and promotes G1-S progression (Godden-Kent et al., 1997; Swanton et al., 1997). The Cyclin D-CDK6 complex is to function to exit from G0 to G1 phase (Laman et al., 2001) and the v-cyc/CDK6 complex is resistant to inhibition by CDK inhibitors by p16, p21 and p27 (Jarviluoma et al., 2004). Thus, its real function has not been elucidated and it was reported that ectopic or overexpression of c-CYC evokes rather cell/DNA damage (Koopal et al., 2007).

2.4 Viral FLICE inhibitory protein (v-FLIP)
KSHV encoded v-flip, a homologue of cellular flip (c-flip) is expressed as co-transcript with v-cyc and translated via internal ribosome entry site (IRES). v-FLIP activates NF-κB to maintain PEL cell tumor phenotype (Guasparri, Keller, and Cesarman, 2004). Inhibition of NF-κB activity and knocking down v-FLIP lead to KSHV infected PEL cell death (Keller, Schattner, and Cesarman, 2000). NF-κB activity is also required for maintenance of KSHV latency (Ye et al., 2008) and v-FLIP, thus, may sustain the viral latency in B cells to stand by for oncogenic transformation and maintain the transformed phenotype (de Oliveira, Ballon, and Cesarman, 2010). Oncogenic activity of v-FLIP was also reported and in transgenic mouse models, v-FLIP expression induces B cell transdifferentiation and tumorigenesis (Ballon et al., 2011). Furthermore, v-FLIP represses cell death with autophagy by interacting Atg3 (Lee et al., 2009).

2.5 Kaposin (K12)
Kaposin is a uniquely transcribed at the edge of the active transcription region of the KSHV genome (Li et al., 2002). There are three frames around this region and probably a major gene is so-called kaposin B whose C-terminal region is corresponding to K12 ORF. Open reading frame (ORF) of KAPO SIN B contains reiterated proline-rich, 23-amino acid direct repeats, since this region includes one of two ori-Lyt sequences (lytic amino acid origin) (Sadler et al., 1999). KAPO SIN B activates p38 mediated mitogen-activated protein kinase [MAPK]-associated protein kinase 2 (MK2) make AU-rich 3’ UTR containing mRNA stabilize (McCormick and Ganem, 2005). Activation of p38, on the other hand, was reported
to induce lytic cycle of the virus (Yoo et al., 2010). Thus, although there is a conflict in KAPOSIN B function in the KSHV latency, a lot of transcripts including T0.7 polyA (-) RNA and k12 mRNA are generated in this region.

2.6 KSHV microRNAs
Importantly, the region between ori-LytR and v-flip ORF is the region for the KSHV microRNA cluster and supplies with 17 mature microRNAs that do something in the viral latency (Boss, Plaisance, and Renne, 2009). As the cellular genomes produce various kinds of microRNA, especially DNA viruses also do (Cullen, 2009). Among them, some of them are targeting cellular genes; miR-K12-11 to BACH1, miR-K12-6-3p to THBS1, miR-K12-4-5p to Rbl2 (Lu et al., 2010), miR-K12-6 and miR-K12-11 to MAF (Hansen et al., 2010) and miR-K9 to rta to tune lytic reactivation finely (Lin et al., 2011), though their accurate transcription units or mechanisms have not been cleared. From now on, micro deletion mutant viruses in which each microRNA is precisely deleted will be required to understand their real sufficiency and necessity for their function, because gross deletion might have an effect on gene expression program around it.

2.7 v-IRF3 (K10.5)
KSHV encodes four genes with homology to human interferon regulatory factors (IRFs) called vIRF-1, -2, -3, -4 whose genes are clustered totally different region far from a lana including locus. And interestingly, one of them, vIRF-3 is expressed in the KSHV latency (Fig. 2). vIRF-3 was reported to be required for the survival of KSHV infected PELs (Wies et al., 2008), suggesting that it is a growth promoting factor by disabling type I and II interferon responses (Schmidt, Wies, and Neipel, 2011), PML-mediated transcriptional repression of survivin (Marcos-Villar et al., 2009), and inhibiting p53 function (Rivas et al., 2001) as well.

Fig. 2. vIRF region of the KSHV genome

2.8 Lytic viral genes and oncogenesis
As mentioned, viral latency genes seems to have pivotal roles for the viral oncogenesis partly because the KSHV related malignancies usually happen in cells with the viral latency. Such genes products, however, do not have immortalizing and/or transforming activity either in vitro or in vivo except v-flip (Ballon et al., 2011). Putative KSHV oncogenes are rather encoded in lytic viral genes. KSHV k1 and v-gpcr (orf72) showed real oncogenic activities (Mutlu et al., 2007). Thus, lytic genes should not be forgot and rather KSHV oncogenic activities should be considered on the pathway of reactivation from latency.
3. KSHV-associated malignancies

Since KHSV was found, extensive studies were performed to prove the involvement of KHSV in many cancers. Related diseases, however, are confined to a few cancers or cancer-like diseases; KS, MCD, and PEL. The other diseases such as multiple myeloma, sarcoidosis and primary pulmonary hypertension could not be KHSV-associated diseases. The former three diseases are certainly related to KSHV, though not hundred percent. Here, we would like to discuss about two B lymphocyte-originated tumors associated with KSHV infection.

3.1 Multicentric castleman’s disease (MCD)

MCD is a disease in which KSHV is involved. But KSHV is not necessarily associated in MCD and KSHV associated MCD is usually seen in AIDS setting (Dupin et al., 1999). KSHV-associated MCD is not associated with Epstein-Barr virus (EBV) (Oksenhendler et al., 1996). In contrast, PEL is usually coinfected with KSHV and EBV in vivo (Ansari et al., 1996). MCD is a B cell lymphoma morphologically resembling plasmablasts without undergoing a germinal center reaction (Parravicini et al., 2000). It is unclear how this disease is established but a KSHV viral load is a decisive factor for exacerbation of MCD (Grandadam et al., 1997) and thus KSHV should have a role in MCD pathogenesis. High level interleukin 6 (IL-6) is a well-known fact in MCD and should do something in MCD pathogenesis (Oksenhendler et al., 1996). B cell markers, CD20 and the memory B cell marker CD27 are usually expressed, but B cell activation markers such as CD23, CD38 and CD30 are not. KSHV gene expression profiles are different from those in KS and PEL. It was reported that viral lytic genes; v-IRF-1 and v-IL-6 and ORF59 (a polymerase processivity factor, PF8) as well as a latent gene; LANA were expressed, suggesting that not a few cells in MCD are in the lytic phase.

3.2 Primary effusion lymphoma (PEL)

PEL is a rare B-cell originated lymphoma, most of which are infected with KSHV and usually emerges in patients suffering from acquired immunodeficiency syndrome (Carbone and Gloghini, 2008) by human immunodeficiency virus-1 (HIV-1) infection. PEL, used to be called body cavity-based lymphoma (BCBL), has been differentiated from the other lymphomas based on a sine qua non etiologic agent, KSHV. This rare lymphoma does not form a solid mass and is spreading along the serous membrane as PEL initially rises in one serous cavity such as a pleural cavity and a peritoneal cavity. Cytologically, it is supposed that the tumor cells are derived from postgerminal center B cells and show a large cell immunoblastic plasmacytoid lymphoma and anaplastic large cell lymphoma and display a non-B, non-T phenotype (Brimo et al., 2007). 70 percent of PEL cases were co-infected with Epstein-Barr virus (EBV) in vivo (Ascoli et al., 1998). However, tightness with KSHV/HHV-8 infection suggests that KSHV/HHV-8 should have an important role for PEL pathogenesis with no doubt, taking into consideration that PEL frequently loses EBV but not KSHV after in vitro establishment of PEL cell lines. Analyses on gene expression profiles of this rare tumor would give us a lot of information on how PEL was formed (Naranatt et al., 2004; Uetz et al., 2006) and we also analyzed three types of typical lymphocyte-originated tumor cell lines-primary effusion lymphoma (PEL) cell lines, T cell leukemia cell lines (TCL), Burkitt lymphoma (BL) cell lines and two sets of normal peripheral blood mononuclear cells (PBMCs)-in order to know how PEL was generated by searching characteristic gene expression profiles (Ueda et al., 2010). As a
result, these cell lines showed respective typical gene expression profiles and classified into clear four groups, PEL, TCL, BL and normal PBMCs. Two B lymphocyte-originated tumor cell lines, PEL and BL cell lines, clearly exhibited distinct gene expression profiles, respectively, which could be consistent with the fact that each was originated from different B-cell stages. KSHV seemed to govern the gene expression profile of the co-infected cell line, even though PEL is often co-infected with EBV in vivo and there was only one line that was co-infected with both KSHV and EBV. This suggests that existence of KSHV promotes PEL formation but not BL. Gene expression profiles of PEL were also distinct from those of KS, suggesting that cell environment affects a gene expression pattern. These data suggested not only that established typical tumor cell lines showed a distinct gene expression profile but also that this profile may be governed by a certain virus.

Fig. 3. Typical genes expression levels in PEL, BL and TCL

About sixty genes were prominently expressed in PEL cell lines, including Angiopoietin 1 (Ang-1, NM001146), methyl CpG binding protein 1 (MBD1, NM015845), interleukin 2 receptor β (IL2Rβ, NM000878) and so on, compared with the other cell lines. The Ang-1 receptor, TIE-2 was not increased in PEL cell line, meaning that an autocrine loop could be unlikely but Ang-1 expression might take an effect in the AIDS environment. CD79A, B and BCL6 were remarkably reduced in PEL cell lines as reported (Du et al., 2002). CD138 (syndecan), CD22 and interferon regulatory factor 4 (IRF4) were relatively higher and CD38 and CD71 were lower in PEL cell lines and might reflect the difference between in vitro and in vivo (Fig. 3). c-myc was certainly higher in BL as BCL6, and IL-6 expression level was not so different but IL-6 receptor genes seemed to be more expressed in PEL and therefore, sensitivity to IL-6 could be higher in PEL.

4. Conclusion

It is very difficult to talking about viral oncogenesis, since we do not have a useful system for observation of the virus infection to pathogenesis, especially for high host-specific viruses. And our DNA array data suggest just that tumor cells show typical gene
expression profiles after establishment of PEL cell lines at an RNA level and it is may be very difficult to account for viral pathogenesis only by gene expression profiles. Furthermore, lytic gene expression should be taken into consideration to understand how PEL is formed and thus, it would be meaningful to find what kinds of gene were typically induced in lytic induction and for much better understanding, convenient viral infection to oncogenesis models in which we can observe continuously.

5. Acknowledgement

We thank all Lab members to prepare this manuscript. We here apologize that we just list a very limited reference and could not take many references to show the facts obtained by researchers due to a limited space.

6. References

Ansari, M. Q., Dawson, D. B., Nador, R., Rutherford, C., Schneider, N. R., Latimer, M. J., Picker, L., Knowles, D. M., and McKenna, R. W. (1996). Primary body cavity-based AIDS-related lymphomas. Am J Clin Pathol 105(2), 221-9.

Ascoli, V., Mastroianni, C. M., Galati, V., Sirianni, M. C., Fruscalzo, A., Pistilli, A., and Lo Coco, F. (1998). Primary effusion lymphoma containing human herpesvirus 8 DNA in two AIDS patients with Kaposi’s sarcoma. Haematologica 83(1), 8-12.

Ballestas, M. E., Chatis, P. A., and Kaye, K. M. (1999). Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 284(5414), 641-4.

Ballon, G., Chen, K., Perez, R., Tam, W., and Cesarman, E. (2011). Kaposi sarcoma herpesvirus (KSHV) vFLIP oncoprotein induces B cell transdifferentiation and tumorigenesis in mice. J Clin Invest 121(3), 1141-53.

Barbera, A. J., Chodaparambil, J. V., Kelley-Clarke, B., Joukov, V., Walter, J. C., Luguer, K., and Kaye, K. M. (2006). The nucleosomal surface as a docking station for Kaposi’s sarcoma herpesvirus LANA. Science 311(5762), 856-61.

Boss, I. W., Plaisance, K. B., and Renne, R. (2009). Role of virus-encoded microRNAs in herpesvirus biology. Trends Microbiol 17(12), 544-53.

Brimo, F., Michel, R. P., Khetani, K., and Auger, M. (2007). Primary effusion lymphoma: a series of 4 cases and review of the literature with emphasis on cytomorphologic and immunocytochemical differential diagnosis. Cancer 111(4), 224-33.

Carbone, A., and Gloghini, A. (2008). KSHV/HHV8-associated lymphomas. Br J Haematol 140(1), 13-24.

Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culepepper, J., Knowles, D. M., and Moore, P. S. (1994). Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266(5192), 1865-9.

Chen, J., Ueda, K., Sakakibara, S., Okuno, T., Parravicini, C., Corbellino, M., and Yamanishi, K. (2001). Activation of latent Kaposi’s sarcoma-associated herpesvirus by demethylation of the promoter of the lytic transactivator. Proc Natl Acad Sci U S A 98(7), 4119-24.

Chen, L., and Lagunoff, M. (2005). Establishment and maintenance of Kaposi's sarcoma-associated herpesvirus latency in B cells. J Virol 79(22), 14383-91.

Cullen, B. R. (2009). Viral and cellular messenger RNA targets of viral microRNAs. Nature 457(7228), 421-5.
de Oliveira, D. E., Ballon, G., and Cesarman, E. (2010). NF-kappaB signaling modulation by EBV and KSHV. Trends Microbiol 18(6), 248-57.
Du, M. Q., Diss, T. C., Liu, H., Ye, H., Hamoudi, R. A., Cabecadas, J., Dong, H. Y., Harris, N. L., Chan, J. K., Rees, J. W., Dogan, A., and Isaacson, P. G. (2002). KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood 100(9), 3415-8.
Friborg, J., Jr., Kong, W., Hottiger, M. O., and Nabel, G. J. (1999). p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402(6764), 889-94.
Garber, A. C., Hu, J., and Renne, R. (2002). Latency-associated nuclear antigen (LANA) cooperatively binds to two sites within the terminal repeat, and both sites contribute to the ability of LANA to suppress transcription and to facilitate DNA replication. J Biol Chem 277(30), 27401-11.
Garrigues, H. J., Rubinchikova, Y. E., Dipersio, C. M., and Rose, T. M. (2008). Integrin alphaVbeta3 Binds to the RGD motif of glycoprotein B of Kaposi's sarcoma-associated herpesvirus and functions as an RGD-dependent entry receptor. J Virol 82(3), 1570-80.
Godden-Kent, D., Talbot, S. J., Boshoff, C., Chang, Y., Moore, P., Weiss, R. A., and Mittnacht, S. (1997). The cyclin encoded by Kaposi's sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J Virol 71(6), 4193-8.
Grandadam, M., Dupin, N., Calvez, V., Gorin, I., Blum, L., Kernbaum, S., Sicard, D., Buisson, Y., Agut, H., Escande, J. P., and Huraux, J. M. (1997). Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis 175(5), 1198-201.
Guasparri, I., Keller, S. A., and Cesarman, E. (2004). KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 199(7), 993-1003.
Han, S. J., Hu, J., Pierce, B., Weng, Z., and Renne, R. (2010). Mutational analysis of the latency-associated nuclear antigen DNA-binding domain of Kaposi's sarcoma-associated herpesvirus reveals structural conservation among gammaherpesvirus origin-binding proteins. J Gen Virol 91(Pt 9), 2203-15.
Hansen, A., Henderson, S., Lagos, D., Nikitenko, L., Coulter, E., Roberts, S., Gratrix, F., Plaisance, K., Renne, R., Bower, M., Kellam, P., and Boshoff, C. (2010). KSHV-encoded miRNAs target MAF to induce endothelial cell reprogramming. Genes Dev 24(2), 195-205.
Hengge, U. R., Ruzicka, T., Tyring, S. K., Stuschke, M., Roggendorf, M., Schwartz, R. A., and Seeber, S. (2002a). Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2(5), 281-92.
Hengge, U. R., Ruzicka, T., Tyring, S. K., Stuschke, M., Roggendorf, M., Schwartz, R. A., and Seeber, S. (2002b). Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2(6), 344-52.
Hu, J., and Renne, R. (2005). Characterization of the minimal replicator of Kaposi's sarcoma-associated herpesvirus latent origin. J Virol 79(4), 2637-42.
Jarviluoma, A., Koopal, S., Rasanen, S., Makela, T. P., and Ojala, P. M. (2004). KSHV viral cyclin binds to p27KIP1 in primary effusion lymphomas. Blood 104(10), 3349-54.
Keller, S. A., Schattner, E. J., and Cesarman, E. (2000). Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 96(7), 2537-42.
Klein, U., Gloghini, A., Gaidano, G., Chadburn, A., Cesarmian, E., Dalla-Favera, R., and Carbone, A. (2003). Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 101(10), 4115-21.

Koopal, S., Furuhjelm, J. H., Jarviluoma, A., Jaamaa, S., Pyakurel, P., Pussinen, C., Wirzenius, M., Biberfeld, P., Alitalo, K., Laiho, M., and Ojala, P. M. (2007). Viral oncogene-induced DNA damage response is activated in Kaposi sarcoma tumorigenesis. PLoS Pathog 3(9), 1348-60.

Lagunoff, M., Bechtel, J., Venetsanakos, E., Roy, A. M., Abbey, N., Herndier, B., McMahon, M., and Ganem, D. (2002). De novo infection and serial transmission of Kaposi's sarcoma-associated herpesvirus in cultured endothelial cells. J Virol 76(5), 2440-8.

Laman, H., Coverley, D., Krude, T., Laskey, R., and Jones, N. (2001). Viral cyclin-cyclin-dependent kinase 6 complexes initiate nuclear DNA replication. Mol Cell Biol 21(2), 624-35.

Lee, J. S., Li, Q., Lee, J. Y., Lee, S. H., Jeong, J. H., Lee, H. R., Chang, H., Zhou, F. C., Gao, S. J., Liang, C., and Jung, J. U. (2009). FLIP-mediated autophagy regulation in cell death control. Nat Cell Biol 11(11), 1355-62.

Li, H., Komatsu, T., Dezube, B. J., and Kaye, K. M. (2002). The Kaposi's sarcoma-associated herpesvirus K12 transcript from a primary effusion lymphoma contains complex repeat elements, is spliced, and initiates from a novel promoter. J Virol 76(23), 11880-8.

Li, M., Lee, H., Yoon, D. W., Albrecht, J. C., Fleckenstein, B., Neipel, F., and Jung, J. U. (1997). Kaposi's sarcoma-associates herpesvirus encodes a functional cyclin. J Virol 71(3), 1984-91.

Lin, X., Liang, D., He, Z., Deng, Q., Robertson, E. S., and Lan, K. (2011). miR-K12-7-5p encoded by Kaposi's sarcoma-associated herpesvirus stabilizes the latent state by targeting viral ORF50/RTA. PLoS One 6(1), e16224.

Liu, J., Martin, H., Shamay, M., Woodard, C., Tang, Q. Q., and Hayward, S. D. (2007). Kaposi's sarcoma-associated herpesvirus LANA protein downregulates nuclear glycogen synthase kinase 3 activity and consequently blocks differentiation. J Virol 81(9), 4722-31.

Lu, F., Stedman, W., Yousef, M., Renne, R., and Lieberman, P. M. (2010). Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus latency by virus-encoded microRNAs that target Rta and the cellular Rbl2-DNMT pathway. J Virol 84(6), 2697-706.

Lukac, D. M., Renne, R., Kirshner, J. R., and Ganem, D. (1998). Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology 252(2), 304-12.

Mann, D. J., Child, E. S., Swanton, C., Laman, H., and Jones, N. (1999). Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. Embo J 18(3), 654-63.

Marcos-Villar, L., Lopitz-Otoa, F., Gallego, P., Munoz-Fontela, C., Gonzalez-Santamaria, J., Campagna, M., Shou-Jiang, G., Rodriguez, M. S., and Rivas, C. (2009). Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. J Virol 83(17), 8849-58.

McCormick, C., and Ganem, D. (2005). The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science 307(5710), 739-41.
Kaposi's Sarcoma-Associated Virus Governs Gene Expression Profiles Toward B Cell Transformation

Moore, P. S., Gao, S. J., Dominguez, G., Cesarsman, E., Lungu, O., Knowles, D. M., Garber, R., Pellett, P. E., McGeoch, D. J., and Chang, Y. (1996). Primary characterization of a herpesvirus agent associated with Kaposi's sarcoma. *J Virol* 70(1), 549-58.

Mutlu, A. D., Cavallin, L. E., Vincent, L., Chiozzini, C., Eroles, P., Duran, E. M., Asgari, Z., Hooper, A. T., La Perle, K. M., Hilsher, C., Gao, S. J., Dittmer, D. P., Rafii, S., and Mesri, E. A. (2007). In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. *Cancer Cell* 11(3), 245-58.

Naranatt, P. P., Krishnan, H. H., Svojanovsky, S. R., Bloomer, C., Mathur, S., and Chandran, B. (2004). Host gene induction and transcriptional reprogramming in Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)-infected endothelial, fibroblast, and B cells: insights into modulation events early during infection. *Cancer Res* 64(1), 72-84.

Oksenhendler, E., Duarte, M., Soulier, J., Cacoub, P., Welker, Y., Cadre, J., Cazals-Hatem, D., Autran, B., Clauvel, J. P., and Raphael, M. (1996). Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. *AIDS* 10(1), 61-7.

Parravicini, C., Chandran, B., Corbellino, M., Berti, E., Paulli, M., Moore, P. S., and Chang, Y. (2000). Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. *Am J Pathol* 156(3), 743-9.

Paulose-Murphy, M., Ha, N. K., Xiang, C., Chen, Y., Gillim, L., Yarco, R., Meltzer, P., Bittner, M., Trent, J., and Zeichner, S. (2001). Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus). *J Virol* 75(10), 4843-53.

Rivas, C., Thlick, A. E., Parravicini, C., Moore, P. S., and Chang, Y. (2001). Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. *J Virol* 75(1), 429-38.

Russo, J. J., Bohenzky, R. A., Chien, M. C., Chen, J., Yan, M., Maddalena, D., Parry, J. P., Peruzzi, D., Edelman, I. S., Chang, Y., and Moore, P. S. (1996). Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). *Proc Natl Acad Sci U S A* 93(25), 14862-7.

Sadler, R., Wu, L., Forghani, B., Renne, R., Zhong, W., Herndier, B., and Ganem, D. (1999). A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus. *J Virol* 73(7), 5722-30.

Sakakibara, S., Ueda, K., Chen, J., Okuno, T., and Yamanishi, K. (2001). Octamer-binding sequence is a key element for the autoregulation of Kaposi's sarcoma-associated herpesvirus ORF50/Lyta gene expression. *J Virol* 75(15), 6894-900.

Sakakibara, S., Ueda, K., Nishimura, K., Do, E., Ohsaki, E., Okuno, T., and Yamanishi, K. (2004). Accumulation of heterochromatin components on the terminal repeat sequence of Kaposi's sarcoma-associated herpesvirus mediated by the latency-associated nuclear antigen. *J Virol* 78(14), 7299-310.

Schmidt, K., Wies, E., and Neipel, F. (2011). Kaposi's Sarcoma-Associated Herpesvirus Viral Interferon Regulatory Factor 3 Inhibits IFN[gamma] and MHC II Expression. *J Virol*.

Stedman, W., Deng, Z., Lu, F., and Lieberman, P. M. (2004). ORC, MCM, and histone hyperacetylation at the Kaposi's sarcoma-associated herpesvirus latent replication origin. *J Virol* 78(22), 12566-75.

Sun, R., Lin, S. F., Gradoville, L., Yuan, Y., Zhu, F., and Miller, G. (1998). A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. *Proc Natl Acad Sci U S A* 95(18), 10866-71.
Suzuki, T., Isobe, T., Kitagawa, M., and Ueda, K. (2010). Kaposi's sarcoma-associated herpesvirus-encoded LANA positively affects on ubiquitylation of p53. Biochem Biophys Res Commun 403(2), 194-7.

Swanton, C., Mann, D. J., Fleckenstein, B., Neipel, F., Peters, G., and Jones, N. (1997). Herpesviral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 390(6656), 184-7.

Toth, Z., Maglinte, D. T., Lee, S. H., Lee, H. R., Wong, L. Y., Brulois, K. F., Lee, S., Buckley, J. D., Laird, P. W., Marquez, V. E., and Jung, J. U. (2010). Epigenetic analysis of KSHV latent and lytic genomes. PLoS Pathog 6(7), e1001013.

Ueda, K., Ito, E., Karayama, M., Ohsaki, E., Nakano, K., and Watanabe, S. (2010). KSHV-infected PEL cell lines exhibit a distinct gene expression profile. Biochem Biophys Res Commun 394(3), 482-7.

Ueda, K., Sakakibara, S., Ohsaki, E., and Yada, K. (2006). Lack of a mechanism for faithful partition and maintenance of the KSHV genome. Virus Res 122(1-2), 85-94.

Uetz, P., Dong, Y. A., Zeretzke, C., Atzler, C., Baiker, A., Berger, B., Rajagopala, S. V., Roupeliava, M., Rose, D., Fossum, E., and Haas, J. (2006). Herpesviral protein networks and their interaction with the human proteome. Science 311(5758), 239-42.

Verma, S. C., Choudhuri, T., Kaul, R., and Robertson, E. S. (2006). Latency-associated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpesvirus interacts with origin recognition complexes at the LANA binding sequence within the terminal repeats. J Virol 80(5), 2243-56.

Wies, E., Mori, Y., Hahn, A., Kremmer, E., Sturzl, M., Fleckenstein, B., and Neipel, F. (2008). The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. Blood 111(1), 320-7.

Xiao, B., Verma, S. C., Cai, Q., Kaul, R., Lu, J., Saha, A., and Robertson, E. S. (2010). Bub1 and CENP-F can contribute to Kaposi's sarcoma-associated herpesvirus genome persistence by targeting LANA to kinetochores. J Virol 84(19), 9718-32.

Ye, F. C., Zhou, F. C., Xie, J. P., Kang, T., Greene, W., Kuhne, K., Lei, X. F., Li, Q. H., and Gao, S. J. (2008). Kaposi's sarcoma-associated herpesvirus latent gene vFLIP inhibits viral lytic replication through NF-kappaB-mediated suppression of the AP-1 pathway: a novel mechanism of virus control of latency. J Virol 82(9), 4235-49.

Yoo, J., Kang, J., Lee, H. N., Aguilar, B., Kafka, D., Lee, S., Choi, I., Lee, J., Ramu, S., Haas, J., Koh, C. J., and Hong, Y. K. (2010). Kaposin-B enhances the PROX1 mRNA stability during lymphatic reprogramming of vascular endothelial cells by Kaposi's sarcoma herpes virus. PLoS Pathog 6(8).
In order to fully understand the nature of viruses, it is important to look at them from both, their basic science and clinical, standpoints. Our goal with this book was to dissect Herpesviridae into its biological properties and clinical significance in order to provide a logical, as well as practical, approach to understanding and treating the various conditions caused by this unique family of viruses. In addition to their up-to-date and extensive text, each chapter is laced with a variety of diagrams, tables, charts, and images, aimed at helping us achieve our goal. We hope that this book will serve as a reference tool for clinicians of various specialties worldwide.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Keiji Ueda, Emi Ito, Masato Karayama, Eriko Ohsaki, Kazushi Nakano and Shinya Watanabe (2012). Kaposi's Sarcoma-Associated Virus Governs Gene Expression Profiles Toward B Cell Transformation, Herpesviridae - A Look Into This Unique Family of Viruses, Dr. George Dimitri Magel (Ed.), ISBN: 978-953-51-0186-4, InTech, Available from: http://www.intechopen.com/books/herpesviridae-a-look-into-this-unique-family-of-viruses/kaposi-s-sarcoma-associated-virus-governs-gene-expression-profiles-toward-b-cell-transformation
